Home - HiFiBiO Therapeutics
Developing Immunotherapies for Patients Transformed by Drug Intelligence Science
Drug Intelligence Science (DIS®) Enhances Clinical Success from Target to Patient
HiFiBiO Therapeutics is pioneering curative immunotherapies for patients with high unmet medical needs. The company is targeting the root cause of disease through its unique Drug Intelligence Science (DIS®) platform. DIS® enables the deep understanding of cellular pathology across various diseases through proprietary single cell technology and AI/ML analytics. This platform is being deployed in target discovery, antibody selection, and predictive biomarker identification to achieve enhanced clinical success for patients.
Proven Track Record of Therapeutic Innovation
We started in 2017 with the goal of leveraging deep immune modulation expertise and cutting edge single cell technology to deliver transformative medicines to patients.
4 Phase I Dose Escalation Trials Completed
6 INDs Filed and Cleared
8 Clinical Candidates Discovered
12+ Partnerships Established